MARKET

PFNX

PFNX

PFENEX
AMEX

Real-time Quotes | Nasdaq Last Sale

9.10
+0.11
+1.22%
After Hours: 9.03 -0.07 -0.80% 16:11 04/09 EDT
OPEN
9.22
PREV CLOSE
8.99
HIGH
9.39
LOW
8.63
VOLUME
230.36K
TURNOVER
--
52 WEEK HIGH
14.00
52 WEEK LOW
5.25
MARKET CAP
311.41M
P/E (TTM)
4136.36
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PFNX stock price target is 18.67 with a high estimate of 20.00 and a low estimate of 17.00.

EPS

PFNX News

More
  • Edited Transcript of PFNX earnings conference call or presentation 11-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 20h ago
  • Should You Worry About Pfenex Inc.'s (NYSEMKT:PFNX) CEO Pay Cheque?
  • Simply Wall St. · 03/16 12:47
  • Pfenex Inc. (PFNX) CEO Eef Schimmelpennink on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/12 01:46
  • Pfenex EPS beats by $0.13, beats on revenue
  • seekingalpha · 03/12 01:10

Industry

Biotechnology & Medical Research
+1.63%
Pharmaceuticals & Medical Research
+0.82%

Hot Stocks

Symbol
Price
%Change

About PFNX

Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.
More

Webull offers kinds of Pfenex Inc stock information, including AMEX:PFNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PFNX stock news, and many more online research tools to help you make informed decisions.